{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:01:40Z","timestamp":1787749300223,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008376","name":"HUS Helsinki University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.imlet.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T11:35:56Z","timestamp":1688470556000},"page":"81-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis"],"prefix":"10.1016","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-6257","authenticated-orcid":false,"given":"Chris","family":"Myllynen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joona","family":"Sarkkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Atula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pentti","family":"Tienari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-108X","authenticated-orcid":false,"given":"Eliisa","family":"Kek\u00e4l\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini M.","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2023.07.001_bib0001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.imlet.2023.07.001_bib0002","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"New England J. Med."},{"key":"10.1016\/j.imlet.2023.07.001_bib0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.imlet.2023.07.001_bib0004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.imlet.2023.07.001_bib0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.imlet.2023.07.001_bib0006","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.imlet.2023.07.001_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev."},{"issue":"2","key":"10.1016\/j.imlet.2023.07.001_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.imlet.2023.07.001_bib0009","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.imlet.2023.07.001_bib0010","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis","volume":"145","author":"Leprince","year":"1990","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"11","key":"10.1016\/j.imlet.2023.07.001_bib0011","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2004.00968.x","article-title":"Associated conditions in myasthenia gravis: response to thymectomy","volume":"11","author":"T\u00e9llez-Zenteno","year":"2004","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.imlet.2023.07.001_bib0012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.imlet.2023.07.001_bib0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2016.05.003","article-title":"Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis","volume":"166-167","author":"Saruhan-Direskeneli","year":"2016","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.imlet.2023.07.001_bib0014","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ana.23691","article-title":"Risk for myasthenia gravis maps to a (151) Pro\u2192Ala change in TNIP1 and to human leukocyte antigen-B*08","volume":"72","author":"Gregersen","year":"2012","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.imlet.2023.07.001_bib0015","doi-asserted-by":"crossref","first-page":"e36603","DOI":"10.1371\/journal.pone.0036603","article-title":"Late onset myasthenia gravis is associated with HLA DRB1\u00d715:01 in the Norwegian population","volume":"7","author":"Maniaol","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.imlet.2023.07.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108672119","article-title":"Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study","volume":"119","author":"Chia","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"9","key":"10.1016\/j.imlet.2023.07.001_bib0017","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41379-022-01070-2","article-title":"Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy","volume":"35","author":"Sarkkinen","year":"2022","journal-title":"Modern Pathol. Offic. J. United States Canadian Acad. Pathol. Inc"},{"key":"10.1016\/j.imlet.2023.07.001_bib0018","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.imlet.2023.07.001_bib0019","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/jnnp.56.5.496","article-title":"Clinical implementation of anti-acetylcholine receptor antibodies","volume":"56","author":"Somnier","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"9","key":"10.1016\/j.imlet.2023.07.001_bib0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"2","key":"10.1016\/j.imlet.2023.07.001_bib0021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imlet.2023.07.001_bib0022","doi-asserted-by":"crossref","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2023.07.001_bib0023","doi-asserted-by":"crossref","first-page":"39716","DOI":"10.1038\/srep39716","article-title":"Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients","volume":"7","author":"Molin","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.imlet.2023.07.001_bib0024","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10","key":"10.1016\/j.imlet.2023.07.001_bib0025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ajh.21815","article-title":"Serum free light chain analysis","volume":"85","author":"Davids","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2023.07.001_bib0026","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.biopha.2017.04.121","article-title":"The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases","volume":"91","author":"Esparvarinha","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.imlet.2023.07.001_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9646209","article-title":"Serological immunoglobulin-free light chain profile in myasthenia gravis patients","author":"Basile","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"5","key":"10.1016\/j.imlet.2023.07.001_bib0028","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/NXI.0000000000000831","article-title":"High \u03ba free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis","volume":"7","author":"Wilf-Yarkoni","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.imlet.2023.07.001_bib0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cca.2022.01.004","article-title":"The role of serum free light chain as biomarker of Myasthenia Gravis","volume":"528","author":"Gambino","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.imlet.2023.07.001_bib0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann. Thorac. Surg."},{"issue":"6","key":"10.1016\/j.imlet.2023.07.001_bib0031","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2183\/pjab.86.588","article-title":"The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine","volume":"86","author":"Nakamura","year":"2010","journal-title":"Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci."},{"issue":"11","key":"10.1016\/j.imlet.2023.07.001_bib0032","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00262-019-02425-6","article-title":"Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope","volume":"68","author":"Martinenaite","year":"2019","journal-title":"Cancer Immunol. Immunother. CII"},{"issue":"1","key":"10.1016\/j.imlet.2023.07.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.imlet.2023.07.001_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinbiochem.2021.03.003","article-title":"Roles of matrix metalloproteinase-7 (MMP-7) in cancer","volume":"92","author":"Liao","year":"2021","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.imlet.2023.07.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104420","article-title":"Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production","volume":"368","author":"Liu","year":"2021","journal-title":"Cell. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2023.07.001_bib0036","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.imlet.2023.07.001_bib0037","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"issue":"7\u20138","key":"10.1016\/j.imlet.2023.07.001_bib0038","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clinbiochem.2013.01.014","article-title":"Serum free light chain reference values: a critical approach","volume":"46","author":"Altinier","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.imlet.2023.07.001_bib0039","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clinbiochem.2018.06.003","article-title":"Reference intervals and diagnostic ranges for serum free \u03ba and free \u03bb immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study","volume":"58","author":"Cotten","year":"2018","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.imlet.2023.07.001_bib0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clinbiochem.2021.02.008","article-title":"Serum free light chain reference intervals in an Optilite and their influence on clinical guidelines","volume":"92","author":"Morales-Garc\u00eda","year":"2021","journal-title":"Clin. Biochem."},{"issue":"3","key":"10.1016\/j.imlet.2023.07.001_bib0041","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.imlet.2023.07.001_bib0042","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13023-021-01860-y","article-title":"Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524782300113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524782300113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:13:34Z","timestamp":1778721214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524782300113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":42,"alternative-id":["S016524782300113X"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2023.07.001","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}